DNA vaccination for prostate cancer: key concepts and considerations

Grace Cole, Joanne McCaffrey, Ahlam A Ali, Helen O McCarthy

Research output: Contribution to journalReview article

11 Citations (Scopus)
187 Downloads (Pure)

Abstract

While locally confined prostate cancer is associated with a low five year mortality rate, advanced or metastatic disease remains a major challenge for healthcare professionals to treat and is usually terminal. As such, there is a need for the development of new, efficacious therapies for prostate cancer. Immunotherapy represents a promising approach where the host's immune system is harnessed to mount an anti-tumour effect, and the licensing of the first prostate cancer specific immunotherapy in 2010 has opened the door for other immunotherapies to gain regulatory approval. Among these strategies DNA vaccines are an attractive option in terms of their ability to elicit a highly specific, potent and wide-sweeping immune response. Several DNA vaccines have been tested for prostate cancer and while they have demonstrated a good safety profile they have faced problems with low efficacy and immunogenicity compared to other immunotherapeutic approaches. This review focuses on the positive aspects of DNA vaccines for prostate cancer that have been assessed in preclinical and clinical trials thus far and examines the key considerations that must be employed to improve the efficacy and immunogenicity of these vaccines.

Original languageEnglish
Article number2
JournalCancer Nanotechnology
Volume6
DOIs
Publication statusPublished - 02 Jul 2015

Fingerprint

DNA Vaccines
vaccines
Prostatic Neoplasms
Vaccination
DNA
deoxyribonucleic acid
cancer
Immunotherapy
Vaccines
Immune system
Tumors
licensing
immune systems
mortality
Licensure
Immune System
therapy
safety
tumors
Clinical Trials

Cite this

@article{3b358d0421764aa68848b261a706c47a,
title = "DNA vaccination for prostate cancer: key concepts and considerations",
abstract = "While locally confined prostate cancer is associated with a low five year mortality rate, advanced or metastatic disease remains a major challenge for healthcare professionals to treat and is usually terminal. As such, there is a need for the development of new, efficacious therapies for prostate cancer. Immunotherapy represents a promising approach where the host's immune system is harnessed to mount an anti-tumour effect, and the licensing of the first prostate cancer specific immunotherapy in 2010 has opened the door for other immunotherapies to gain regulatory approval. Among these strategies DNA vaccines are an attractive option in terms of their ability to elicit a highly specific, potent and wide-sweeping immune response. Several DNA vaccines have been tested for prostate cancer and while they have demonstrated a good safety profile they have faced problems with low efficacy and immunogenicity compared to other immunotherapeutic approaches. This review focuses on the positive aspects of DNA vaccines for prostate cancer that have been assessed in preclinical and clinical trials thus far and examines the key considerations that must be employed to improve the efficacy and immunogenicity of these vaccines.",
author = "Grace Cole and Joanne McCaffrey and Ali, {Ahlam A} and McCarthy, {Helen O}",
year = "2015",
month = "7",
day = "2",
doi = "10.1186/s12645-015-0010-5",
language = "English",
volume = "6",
journal = "Cancer Nanotechnology",
issn = "1868-6958",
publisher = "Springer Science + Business Media",

}

DNA vaccination for prostate cancer: key concepts and considerations. / Cole, Grace; McCaffrey, Joanne; Ali, Ahlam A; McCarthy, Helen O.

In: Cancer Nanotechnology, Vol. 6, 2, 02.07.2015.

Research output: Contribution to journalReview article

TY - JOUR

T1 - DNA vaccination for prostate cancer: key concepts and considerations

AU - Cole, Grace

AU - McCaffrey, Joanne

AU - Ali, Ahlam A

AU - McCarthy, Helen O

PY - 2015/7/2

Y1 - 2015/7/2

N2 - While locally confined prostate cancer is associated with a low five year mortality rate, advanced or metastatic disease remains a major challenge for healthcare professionals to treat and is usually terminal. As such, there is a need for the development of new, efficacious therapies for prostate cancer. Immunotherapy represents a promising approach where the host's immune system is harnessed to mount an anti-tumour effect, and the licensing of the first prostate cancer specific immunotherapy in 2010 has opened the door for other immunotherapies to gain regulatory approval. Among these strategies DNA vaccines are an attractive option in terms of their ability to elicit a highly specific, potent and wide-sweeping immune response. Several DNA vaccines have been tested for prostate cancer and while they have demonstrated a good safety profile they have faced problems with low efficacy and immunogenicity compared to other immunotherapeutic approaches. This review focuses on the positive aspects of DNA vaccines for prostate cancer that have been assessed in preclinical and clinical trials thus far and examines the key considerations that must be employed to improve the efficacy and immunogenicity of these vaccines.

AB - While locally confined prostate cancer is associated with a low five year mortality rate, advanced or metastatic disease remains a major challenge for healthcare professionals to treat and is usually terminal. As such, there is a need for the development of new, efficacious therapies for prostate cancer. Immunotherapy represents a promising approach where the host's immune system is harnessed to mount an anti-tumour effect, and the licensing of the first prostate cancer specific immunotherapy in 2010 has opened the door for other immunotherapies to gain regulatory approval. Among these strategies DNA vaccines are an attractive option in terms of their ability to elicit a highly specific, potent and wide-sweeping immune response. Several DNA vaccines have been tested for prostate cancer and while they have demonstrated a good safety profile they have faced problems with low efficacy and immunogenicity compared to other immunotherapeutic approaches. This review focuses on the positive aspects of DNA vaccines for prostate cancer that have been assessed in preclinical and clinical trials thus far and examines the key considerations that must be employed to improve the efficacy and immunogenicity of these vaccines.

U2 - 10.1186/s12645-015-0010-5

DO - 10.1186/s12645-015-0010-5

M3 - Review article

C2 - 26161151

VL - 6

JO - Cancer Nanotechnology

JF - Cancer Nanotechnology

SN - 1868-6958

M1 - 2

ER -